Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) had its price target reduced by stock analysts at Morgan Stanley from $5.90 to $5.60 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has an "equal weight" rating on the stock. Morgan Stanley's price target points to a potential upside of 96.15% from the company's current price.
Several other research analysts have also recently weighed in on RXRX. JPMorgan Chase & Co. lowered their price target on shares of Recursion Pharmaceuticals from $10.00 to $7.00 and set an "overweight" rating on the stock in a report on Monday. Weiss Ratings restated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a report on Thursday, October 15th. Wall Street Zen raised Recursion Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, November 7th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $7.52.
Check Out Our Latest Report on RXRX
Recursion Pharmaceuticals Trading Up 5.0%
Shares of NASDAQ:RXRX traded up $0.14 on Wednesday, hitting $2.85. The company had a trading volume of 9,283,040 shares, compared to its average volume of 19,693,332. Recursion Pharmaceuticals has a 1-year low of $2.50 and a 1-year high of $5.24. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -3.17 and a beta of 1.15. The stock has a 50 day moving average price of $3.75 and a 200 day moving average price of $3.47.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported ($0.22) earnings per share for the quarter, meeting the consensus estimate of ($0.22). The company had revenue of $18.55 million for the quarter, compared to analyst estimates of $14.81 million. Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative return on equity of 47.85%. During the same period in the prior year, the firm earned ($0.36) earnings per share. Sell-side analysts anticipate that Recursion Pharmaceuticals will post -0.89 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Recursion Pharmaceuticals news, Director Robert Hershberg sold 25,000 shares of the stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $5.00, for a total transaction of $125,000.00. Following the transaction, the director owned 162,156 shares in the company, valued at $810,780. This represents a 13.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 40,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $3.88, for a total transaction of $155,200.00. Following the transaction, the director directly owned 6,068,287 shares in the company, valued at $23,544,953.56. This represents a 0.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 167,408 shares of company stock worth $701,276 in the last quarter. 6.65% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Recursion Pharmaceuticals
Institutional investors have recently made changes to their positions in the stock. Jump Financial LLC grew its stake in Recursion Pharmaceuticals by 145.0% during the third quarter. Jump Financial LLC now owns 2,497,200 shares of the company's stock worth $10,313,000 after buying an additional 1,478,027 shares in the last quarter. First Trust Advisors LP increased its holdings in Recursion Pharmaceuticals by 16.8% in the 3rd quarter. First Trust Advisors LP now owns 3,551,885 shares of the company's stock valued at $14,669,000 after buying an additional 510,056 shares during the period. Landscape Capital Management L.L.C. acquired a new position in shares of Recursion Pharmaceuticals in the 3rd quarter valued at approximately $243,000. Voya Investment Management LLC raised its position in shares of Recursion Pharmaceuticals by 258.7% in the 3rd quarter. Voya Investment Management LLC now owns 351,438 shares of the company's stock valued at $1,451,000 after buying an additional 253,455 shares in the last quarter. Finally, HighTower Advisors LLC raised its position in shares of Recursion Pharmaceuticals by 133.6% in the 3rd quarter. HighTower Advisors LLC now owns 99,268 shares of the company's stock valued at $410,000 after buying an additional 56,782 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.